California is currently home to 5600 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Drug-Induced Liver Injury (DILI) Network Retrospective
Recruiting
The purpose of this study is to establish retrospectively a nationwide registry of patients who have suffered drug-induced liver injury (DILI), and to collect, immortalize, and store serum, DNA, and lymphocytes from these patients. ILIAD will serve as a resource for subsequent mechanistic investigations into the basis of severe idiosyncratic DILI. The primary goal of the ILIAD protocol is to create: (a) a clinical database consisting of individuals who have experienced severe DILI and the releva... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
04/16/2025
Locations: University of Southen California, Los Angeles, California
Conditions: Drug Induced Liver Injury
DILIN - Prospective Study
Recruiting
The purpose of this study is to identify individuals who have suffered a liver injury arising as an idiosyncratic reaction to a prescription drug or a complementary and alternative medicine. Recently added acute cases enrollment that meets criteria to the protocol. Also added Fibroscans to the protocol that will be completed at baseline and follow-up on chronic subjects.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
04/16/2025
Locations: University of Southern California, Los Angeles, California
Conditions: Liver Diseases
Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
Recruiting
PRISMA, is a pregnancy registry study, focused on comprehensively collecting information about pregnancy in women with chronic neurological conditions from across the United States and internationally. Depending on their specific condition (MS, CIS, NMOSD, or other) and their specific treatment, participants will be asked to contribute to different aspects of the study. (1) The biosamples will be blood, breast milk, infant stool, and maternal stool samples, collected at specific time points. (2... Read More
Gender:
FEMALE
Ages:
Between 18 years and 64 years
Trial Updated:
04/15/2025
Locations: University of California-San Francisco, San Francisco, California
Conditions: Multiple Sclerosis, Clinically Isolated Syndrome, NMOSD, Myasthenia Gravis
Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants
Recruiting
The main objective of the study is to assess the safety and tolerability of AMG 378 as single or multiple doses in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/15/2025
Locations: Orange County Research Center, Lake Forest, California
Conditions: Healthy Volunteers
EluPro Antibiotic-Eluting BioEnvelope Registry
Recruiting
A Multi-Center Registry Study Evaluating Participants Who Receive EluPro Antibiotic-Eluting BioEnvelope During CIED Implantation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: UC San Diego Health, La Jolla, California
Conditions: Cardiac Arrhythmias
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Recruiting
This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 administered orally in subjects with advanced hematologic malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: City of Hope National Medical Center, Duarte, California
Conditions: Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Relapsed/refractory AML, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes, Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
A Study of Oral YUQ-A1007 in Healthy Volunteers
Recruiting
YUQ-A1007 is a novel gut-enriched AhR agonist. The nonclinical pharmacology study indicated that YUQ-A1007 has the potential to treat IBD. YUQ-A1007 has not been evaluated in human clinical studies. This study is first-in-human (FIH) study of YUQ-A1007. The goal of this trial is to evaluate the safety, tolerability, and pharmacokinetics of oral YUQ-A1007.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/15/2025
Locations: Anaheim Clinical Trials, Anaheim, California
Conditions: Healthy
National Program to Overcome Pelvic Pain studY (POPPY)
Recruiting
A randomized, parallel-group, investigator-blinded, comparative effectiveness trial of a fully remote, videoconference-based pelvic floor yoga program versus a physical conditioning program for women with chronic pelvic pain syndrome.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: University of California San Francisco, San Francisco, California
Conditions: Chronic Pelvic Pain Syndrome (CPPS), Chronic Pelvic Pain Syndrome, Chronic Pelvic Pain
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
Recruiting
This study is open to adults aged 55 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose. This study has 4 treatment groups. Participants are put into groups randomly, which means by chance. Initially participants can join a BI 1584862 and a placebo group; then more participants are put randomly in 2... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
04/15/2025
Locations: Global Research Management, Glendale, California
Conditions: Geographic Atrophy
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Recruiting
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NNC0519-0130 (a new medicine), semaglutide (a medicine that doctors can already prescribe), or placebo (a "dummy" substance). Which treatment the participant will get is decided by chance. The study wil... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: N America Res Inst - San Dimas, San Dimas, California
Conditions: Chronic Kidney Disease
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
Recruiting
The goal of this clinical trial is to learn if a new contact lens device can record patterns in eye pressure for 24 hours in adults with glaucoma and in healthy participants. The main questions it aims to answer are: * Is the contact lens device able to detect patterns in eye pressure that happens naturally between nighttime and daytime? * Are the contact lens recording patterns similar when repeated one week later? * What eye problems do participants have when wearing contact lens for up to 2... Read More
Gender:
ALL
Ages:
Between 22 years and 80 years
Trial Updated:
04/15/2025
Locations: Nvision Clinical Reseacrh, LLC, Fullerton, California
Conditions: Glaucoma, GLAUCOMA 1, OPEN ANGLE, D (Disorder), Ocular Hypertension, Ocular Hypertension (OH), Ocular Hypertension Glaucoma, IOP, Intraocular Pressure, Glaucoma Open-Angle, Glaucoma and Ocular Hypertension, Glaucoma Patients and Healthy Controls, Normal Tension Glaucoma (NTG)
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
Recruiting
This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged at least 18 years with LSC. Study details include: The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The follow-up duration after treatment will be 12 weeks. The number of visits will be 6.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Center for Dermatology Clinical Research- Site Number : 8400226, Fremont, California
Conditions: Lichen Simplex Chronicus